Nasal administration of recombinant rat IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination

Simple item page
dc.contributor.authorDeretzi, G.en
dc.contributor.authorZou, L. P.en
dc.contributor.authorPelidou, S. H.en
dc.contributor.authorNennesmo, I.en
dc.contributor.authorLevi, M.en
dc.contributor.authorWahren, B.en
dc.contributor.authorMix, E.en
dc.contributor.authorZhu, J.en
dc.date.accessioned2015-11-24T19:02:37Z
dc.date.available2015-11-24T19:02:37Z
dc.identifier.issn0896-8411-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19819
dc.rightsDefault Licence-
dc.subjectAdministration, Intranasalen
dc.subjectAnimalsen
dc.subjectAutoimmune Diseases/immunology/pathology/*therapyen
dc.subjectDemyelinating Diseases/immunology/pathology/*therapyen
dc.subjectDisease Models, Animalen
dc.subjectHumansen
dc.subjectImmunoglobulin G/blood/classificationen
dc.subjectInterferon-gamma/secretionen
dc.subjectInterleukin-4/*administration & dosageen
dc.subjectLymphocyte Activationen
dc.subjectMaleen
dc.subjectNeuritis/immunology/pathology/*therapyen
dc.subjectRatsen
dc.subjectRats, Inbred Lewen
dc.subjectRecombinant Proteins/administration & dosageen
dc.titleNasal administration of recombinant rat IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelinationen
heal.abstractExperimental autoimmune neuritis (EAN) is a CD4(+)T cell-mediated demyelinating disease of the peripheral nervous system (PNS) and serves as an experimental model for human immune-demyelinating neuropathies. In this study, we examined the effect of recombinant rat interleukin-4 (rrIL-4) on chronic EAN in Lewis rats induced by immunization with P0 peptide 180-199 and complete Freund's adjuvant (CFA). We estimated that nasal administration of rrIL-4, in dose ranges of 0.1-1 microg/rat/day in the initial phase of EAN, decreased the severity and the duration of clinical EAN. Hyporesponsiveness of T cells, downregulation of Th1 cell responses (INF-gamma), but increased levels of specific IgG1 isotypes document that nasal administration of rrIL-4 was systemically immune effective. Low grade inflammation and complete lack of regional demyelination within the sciatic nerves were seen in rrIL-4 treated rats. Based on these observations we suggest that nasal administration of IL-4 could be further evaluated, considering its possible use in human immune-demyelinating neuropathies.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1006/jaut.1998.0259-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10047428-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0896841198902591/1-s2.0-S0896841198902591-main.pdf?_tid=dbc79bafdaabdd7c6e9125f744295200&acdnat=1332844632_e8adf78b9b62b97a8f7c529eb9063397-
heal.journalNameJ Autoimmunen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1999-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.74 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ